Enhancing go-to-market strategies with real-world data
Our series exploring the value of real-world data (RWD) throughout the pharmaceutical product life...
Our series exploring the value of real-world data (RWD) throughout the pharmaceutical product life...
In our ongoing series, we have been discussing the value of real-world data (RWD) throughout the...
Two years ago, HealthVerity launched the Maternal Outcomes Masterset (MOM) to address the...
Historically, pharmaceutical manufacturers leveraged retail pharmacy prescriptions to identify...
The COVID-19 pandemic illustrated how vital government communications can be for effective public...
As real-world data (RWD) continues to be increasingly used by the pharmaceutical industry and...
Medicaid provides much-needed healthcare coverage to over 70 million people, almost half of whom...
The use of real-world data (RWD) in pharmaceutical development is becoming increasingly prevalent...
While the CDC is considered the nation’s leading authority on infectious diseases, it is also...
An interview with Kristijan Kahler, executive director of innovation evidence at Novartis While...
Healthcare data now accounts for approximately 30% of global data volume and with this surge in data, life sciences organizations have access to more information than ever before. Some disruptions expand what you can do: new data owners entering the ...